anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Malnutrition is a significant concern affecting the elderly, necessitating a complex assessment. This study aims to deepen the understanding of factors associated with the assessment of malnutrition in the elderly by comparing single- and multi-parameter approaches. In this cross-sectional study, 154 individuals underwent a comprehensive geriatric assessment (CGA). Malnutrition risk was determined using the mini nutritional assessment (MNA). Additional factors assessed included sarcopenia, polypharmacy, depression, appetite, handgrip strength, and gait speed. Phase angle (PA) and body composition were measured using bioelectrical impedance analysis (BIA). The MNA identified a malnutrition risk in 36.8% of individuals. The geriatric depression scale (GDS) and PA demonstrated moderate effectiveness in assessing malnutrition risk, with AUC values of 0.69 (95% CI: 0.60-0.78) and 0.62 (95% CI: 0.54-0.72), respectively. A logistic regression model incorporating handgrip strength, skeletal muscle mass, sarcopenia, osteoporosis, depression, specific antidepressant use, mobility, appetite, and smoking achieved superior performance in predicting malnutrition risk, with an AUC of 0.84 (95% CI: 0.77-0.91). In conclusion, this study demonstrates that integrating multiple parameters into a composite model provides a more accurate and comprehensive assessment of malnutrition risk in elderly adults.
Death has been reported in children who have accidentally ingested OTFC. 

Patients and their caregivers must be informed that OTFC contains a medicine in an amount which can be fatal to a child. Healthcare providers and dispensing pharmacists must specifically question patients or caregivers about the presence of children in the home (on a full time or visiting basis) and counsel them regarding the dangers to children from inadvertent exposure. 

Patients and their caregivers must be instructed to keep both used and unused dosage units out of the reach of children. While all units should be disposed of immediately after use, partially consumed units represent a special risk to children. In the event that a unit is not completely consumed it must be properly disposed as soon as possible.

Detailed instructions for the proper storage, administration, disposal, and important instructions for managing an overdose of OTFC are provided in the OTFC Medication Guide. Encourage patients to read this information in its entirety and give them an opportunity to have their questions answered.
Patients allocated to receive conventional chemotherapy will be treated with methotrexate (1 mg/kg intramuscular) with rescue of folinic acid (15mg orally). In cases of chemoresistance, second-line chemotherapy will be performed with actinomycin-D (Act-D) 1.25 mg intravenous pulse every 14 days. The third line of chemotherapy will be the EMA/CO regimen (reserving the EP / EMA regimen (E, cisplatin, MTX / Act-D) for the fourth line.
Perphenazine and amitriptyline hydrochloride should not be given concomitantly with guanethidine or similarly acting compounds, since amitriptyline, like other tricyclic antidepressants, may block the antihypertensive effect of these compounds.

Because of the atropine like activity of amitriptyline, this product should be used with caution in patients with a history of urinary retention or with angle-closure glaucoma. In patients with angle-closure glaucoma, even average doses may precipitate an attack.

It should be used with caution also in patients with convulsive disorders. Dosage of anticonvulsive agents may have to be increased.

Patients with cardiovascular disorders should be watched closely. Tricyclic antidepressants, including amitriptyline hydrochloride, particularly when given in high doses, have been reported to produce arrhythmias, sinus tachycardia, and prolongation of the conduction time. Myocardial infarction and stroke have been reported with drugs of this class.

Close supervision is required when amitriptyline hydrochloride is given to hyperthyroid patients or those receiving thyroid medication.

This product may enhance the response to alcohol and the effects of barbiturates and other CNS depressants. In patients who may use alcohol excessively, it should be borne in mind that the potentiation may increase the danger inherent in any suicide attempt or overdosage. Delirium has been reported with concurrent administration of amitriptyline and disulfiram.
OBJECTIVE: This article outlines interventions used to improve outcomes for patients with hypoxic-ischemic brain injury after cardiac arrest.
LATEST DEVELOPMENTS: Emergent management of patients after cardiac arrest requires prevention and treatment of primary and secondary brain injury. Primary brain injury is minimized by excellent initial resuscitative efforts. Secondary brain injury prevention requires the detection and correction of many pathophysiologic processes that may develop in the hours to days after the initial arrest. Key physiologic parameters important to secondary brain injury prevention include optimization of mean arterial pressure, cerebral perfusion, oxygenation and ventilation, intracranial pressure, temperature, and cortical hyperexcitability. This article outlines recent data regarding the treatment and prevention of secondary brain injury. Different patients likely benefit from different treatment strategies, so an individualized approach to treatment and prevention of secondary brain injury is advisable. Clinicians must use multimodal sources of data to prognosticate outcomes after cardiac arrest while recognizing that all prognostic tools have shortcomings.
ESSENTIAL POINTS: Neurologists should be involved in the postarrest care of patients with hypoxic-ischemic brain injury to improve their outcomes. Postarrest care requires nuanced and patient-centered approaches to the prevention and treatment of primary and secondary brain injury and neuroprognostication.
Lower limb amputation (LLA) results in the loss of the biological joint structures such as the ankle and knee, along with the associated musculature. This reduces joint mobility and strength and thus adversely affects amputees' ability to maintain balance. As a result, individuals with a LLA have been shown to fall more often when compared to age-matched and otherwise healthy individuals. In addition, individuals with LLA also have an increased fear of falling and reduced social participation because of this fear. Improving balance ability, reducing falls and fear of falling in this patient group through effective balance training interventions would have a number of socio-economic benefits. Such benefits may include but are not limited to reduced care costs, reduced burden on healthcare services and an improved sense of patient well-being. Therefore, the main aim of the current randomised control trial (RCT) is to investigate whether taking part in a games console based-balance intervention, improves experienced LLAs balance ability. The RCT also aims to assess how this intervention affects an amputee's falls rate, fear of falling and quality of life. After providing informed consent, unilateral lower limb amputees will be randomly allocated to one of two groups; an experimental group (12-week balance training intervention) or a control group (no intervention). Amputees in the experimental group will be loaned the use of a games console for the duration of the home-based intervention. Balance ability, falls rate, fear of falling and quality of life will be assessed prior to and post the intervention period as well as after three months following the end of the intervention period. Falls rate will also assessed one year post the intervention period. Results from the current study will provide evidence for the use of games-console based balance interventions in improving balance and falls outcomes for LLA.
Pulmonary delivery of dry powder formulations by aerosol inhalation has received much attention as an attractive alternative to intravenous, intramuscular, and subcutaneous injection, since this approach eliminates the necessity for injection syringes and needles. The present invention provides dry powder filled cellulose-based capsules having particular utility for use with dry powder inhalers. Such capsules not only readily coordinate with conventional DPIs but also coordinate with conventional powder filling technologies, thereby saving time, labor and cost. The invention further provides a novel procedure for determining, ab initio, appropriate and optimal conditions for preparing such powder filled capsules. Specifically, when packaging dry powder formulations for long-term storage, it is important to ensure that the water content of the powder does not exceed the critical moisture point, that point at which the powder loses physical and chemical stability. The present invention describes means for predicting equilibrium moisture contents, which in turn can be used to establish suitable capsule preparation and filling protocols.
1,268,866. Threo rich beta-p-methylsulphonyl phenylserine. SUMITOMO CHEMICAL CO. Ltd. 24 July, 1969, No. 48078/71. Divided out of 1,268,865. Heading C2C. The invention comprises a process for making the crude title compound by contacting pmethylsulphonylbenzaldehyde with an alkali metal salt of glycine in an alcohol solvent using 2 moles of the aldehyde per mole of glycine. The threo rich compound can be isolated by acidifying the crude product to precipitate unreacted aldehyde (remove by filtration) and neutralizing the filtrate.
The participants in this group will receive a 12-week rehabilitation program (2x/week) including, education, stretching, strengthening, proprioceptive exercises of the lower limb and cardiovascular training using low-impact activities, in addition to walking aid adjustment using a telecommunication software (Reacts®, Facetime® or Skype®). General information about pain control, such as ice application and medication usage will also be provided.
For the control population, 120 control subjects, including 30 minors, that is to say as many as patients. For control subjects, a MEG-EEG exam.
A method and apparatus for electrofusing a plurality of cancer cell types to dendritic cells (DCs) which results in the formation of electrofused DC-tumor cells with high efficiency and high viability. The method comprises subjecting the cells with multiple pulses of voltage in specially designed media. This is the first documentation of electrofusion of large numbers of DCs and tumor cells. Evidence demonstrates those cells contain all essential DC molecules and express tumor antigens. A single vaccination of animals with pre-existing tumors results in substantial erradication of tumors and cure of animals. The electrofused-cells can be used immediately. These fusion hybrids are to be used for the treatment of cancer directly as vaccines or indirectly by activating immune lymphocytes for adoptive immunotherapy.
This article reviews the correlation between presepsin and sepsis and the resulting acute respiratory distress syndrome (ARDS). ARDS is a severe complication of sepsis. Despite the successful application of protective mechanical ventilation, restrictive fluid therapy, and neuromuscular blockade, which have effectively reduced the morbidity and mortality associated with ARDS, the mortality rate among patients with sepsis-associated ARDS remains notably high. The challenge lies in the prediction of ARDS onset and the timely implementation of intervention strategies. Recent studies have demonstrated significant variations in presepsin (PSEP) levels between patients with sepsis and those without, particularly in the context of ARDS. Moreover, these studies have revealed substantially elevated PSEP levels in patients with sepsis-associated ARDS compared to those with nonsepsis-associated ARDS. Consequently, PSEP emerges as a valuable biomarker for identifying patients with an increased risk of sepsis-associated ARDS and to predict in-hospital mortality.
BACKGROUND: Off-the-shelf stems offer a wide variety of fixation methods for revision arthroplasty and intercalary tumour implants. However, in extensive defects or needed resection with minimal bone stock left, solid fixation is often not feasible with these implants. Custom-made stem solutions (CSS) offer a viable alternative in these cases to achieve joint preservation.
METHODS: Between 2017 and 2024 14 patients (15 implants) were treated in a single-centre study. CSS were indicated if the remaining bone stock was deemed insufficient for normal stem fixation due to tumour resection or previous operations. Postoperative analysis was conducted to evaluate the functional outcome as well as revision rates.
RESULTS: Implantation was possible in all cases, during the follow-up of 30 (SD 18; 6-66) months revision was needed in five cases; with one aseptic loosening, one screw loosening and three PJI cases. Mean MSTS score was 24 (SD 5; 17-30).
CONCLUSION: Custom-made stem solutions show promising results in extreme cases. Especially as a preservation of the joint is possible, this treatment algorithm should be considered on a case-by-case basis.
In all clinical studies, dosage was initiated at a subtherapeutic level and gradually titrated to therapeutic response. The dosage should be increased to achieve a maximum therapeutic effect, balanced against the principal side effects of nausea, dizziness, somnolence, and dyskinesia.

The recommended starting dose for Parkinson’s disease is 0.25 mg 3 times daily. Based on individual patient response, dosage should then be titrated with weekly increments as described in Table 5. After week 4, if necessary, daily dosage may be increased by 1.5 mg/day on a weekly basis up to a dose of 9 mg/day, and then by up to 3 mg/day weekly to a total dose of 24 mg/day. Doses greater than 24 mg/day have not been tested in clinical trials.

When ropinirole hydrochloride tablet is administered as adjunct therapy to L-dopa, the concurrent dose of L-dopa may be decreased gradually as tolerated. L-dopa dosage reduction was allowed during the advanced Parkinson’s disease (with L-dopa) study if dyskinesias or other dopaminergic effects occurred. Overall, reduction of L-dopa dose was sustained in 87% of patients treated with ropinirole hydrochloride tablets and in 57% of patients on placebo. On average the L-dopa dose was reduced by 31% in patients treated with ropinirole hydrochloride tablets.

Ropinirole hydrochloride for Parkinson’s disease patients should be discontinued gradually over a 7-day period. The frequency of administration should be reduced from 3 times daily to twice daily for 4 days. For the remaining 3 days, the frequency should be reduced to once daily prior to complete withdrawal of ropinirole hydrochloride tablets.
The invention provides a new application method of Flower of Hibiscus manihot L.. The new application method uses Flower of Hibiscus manihot L. to prepare a medicine for treating and preventing prostate diseases. The invention also provides an another new application method of Flower of Hibiscus manihot L.. The another new application method uses the Flower of Hibiscus manihot L. to prepare a health product or treating and preventing prostate diseases. A preparation method of a Hibiscus manihot L. Flower water decoction for preventing and treating the prostate diseases comprises the following steps: taking a Hibiscus manihot L. Flower raw material, adding water, decocting the Hibiscus manihot L. Flower raw material for 0.5-1h, filtering the obtained decoction, and collecting the obtained filtrate; and adding water to filter residues, decocting the filter residues for 0.5-1h, filtering the obtained decoction, and mixing above two filtrates to obtain the Hibiscus manihot L. Flower water decoction. The purpose of the invention is to provide an application of the Hibiscus manihot L. Flower in the preparation of the product for preventing and treating the prostate diseases. A traditional Chinese medicinal preparation and the health product prepared from the Flower of Hibiscus manihot L. have obvious improvement effects on prostatitis and prostatic hyperplasia, can substantially reduce the prostatic hyperplasia index, reduces the level of DHT and T in serum, and can substantially improve the level of E2 in the serum.
Subjects received 3 doses of Cervarix vaccine. Cervarix vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm according to a 0, 1, 6-month schedule.
Sympathetic stimulation is necessary in supporting circulatory function in congestive heart failure, and beta-blockade carries the potential hazard of further depressing myocardial contractility and precipitating more severe failure. In patients who have heart failure controlled by digitalis and/or diuretics, sotalol hydrochloride tablets (AF) should be administered cautiously. Both digitalis and sotalol slow AV conduction. As with all beta-blockers, caution is advised when initiating therapy in patients with any evidence of left ventricular dysfunction. In a pooled data base of four placebo-controlled AFIB/AFL and PSVT studies, new or worsening CHF occurred during therapy with sotalol (AF) in 5 (1.2%) of 415 patients. In these studies patients with uncontrolled heart failure were excluded (i.e.,NYHA Functional Classes III or IV). In other premarketing sotalol studies, new or worsened congestive heart failure (CHF) occurred in 3.3% (n=3257) of patients and led to discontinuation in approximately 1% of patients receiving sotalol. The incidence was higher in patients presenting with sustained ventricular tachycardia/fibrillation (4.6%, n=1363), or a prior history of heart failure (7.3%, n=696). Based on a life-table analysis, the one-year incidence of new or worsened CHF was 3% in patients without a prior history and 10% in patients with a prior history of CHF. NYHA Classification was also closely associated to the incidence of new or worsened heart failure while receiving sotalol (1.8% in 1395 Class I patients, 4.9% in 1254 Class II patients and 6.1% in 278 Class III or IV patients).
Before the training program based on the Precede-Proceed Model is applied to the 70 individuals who care for stroke home care patients, the evaluation of the caregivers will be made in the hospital meeting room. After the training is given to the caregivers, the first evaluation will be made at the 8th week in order to determine the changes in their caregiving reactions and social support perceptions after the training is completed. In the 16th week after the completion of the training, a final evaluation will be made in the hospital meeting room in order to determine the changes in caregiver reactions and social support perceptions.
PURPOSE: A foundation composition containing capsulated colorant and a method for manufacturing the same are provided to express natural color. CONSTITUTION: A foundation composition containing capsulated colorant contains 1-20 weight% of capsulated colorant, 2-40 weight% of oil part of silicon oil, 0.1-30 weight% of aqueous part, 5-96.89 weight% of powder part and 0.01-5 weight% of tackifier. The capsulated colorant is iron oxide, titanium oxide or boron nitride. The oil part is cyclomethicone, sorbitan isostearate, dimethicone, cyclomethicone/dimethicone cross polymer, phenyldimethicone, octyl methoxy cinnamate, PEG-8 dimethicone or PEG-10 dimethicone. The aqueous part is glycerin or butylenes glycol or mixture thereof. The powder part is polymethyl methacrylate, talc or magnesium sulfate.
An exercise recommendation system determines workout plans for users. The exercise recommendation system receives a profile of a user and a level of variance selected by the user. The profile includes a history of exercises the user has performed, available gym equipment, and exercise goals. The exercise recommendation system inputs the profile to a machine learning model configured to rank a set of exercises for a user to perform. The exercise recommendation system modifies the ranking of exercises based on the level of variance selected by the user. Modification of the ranking is greater for a first level of variance than for a second level of variance less than the first level of variance. The exercise recommendation system generates a workout plan for display within a user interface to the user based on the modified ranking.
Assay-guided affinity fractionation and reverse phase high pressure liquid chromatography (HPLC) methodology to isolate, test and characterize the most active water-soluble ingredients within Cat's Claw, or Uncaria tomentos. These components appear to account for the majority of the amyloid or A.beta.  fibrillogenesis inhibitory activity. Individual fractions and/or compounds as isolated by HPLC are tested in relevant in vitro and/or animal models, and found to consistently demonstrate inhibition of amyloid or A.beta.  fibrillogenesis. Related extraction methods are disclosed.
PURPOSE:To obtain a safe bathing agent, excellent in feeling of use and safe for the human body by using a natural ingredient of calcium carbonate as a principal ingredient as a new blending ingredient in a bathing agent. CONSTITUTION:This bathing agent comprises a sandy coral fossil or coral sand, produced from the nature and hitherto considered as a blending ingredient in a bathing agent. An organic acid or a concentrate of seawater such as crude salt may be blended therewith. This bathing agent is added to bath water, which is kept under weak alkaline conditions by mild reaction thereof with water to improve the feeling of use of the bath water. The coral fossil or coral sand has an ecological and chemical tissue as opposed to a mineral resource or an industrial product. Ingredients eluted therefrom do not damage the human body at all. Furthermore, since the coral fossil or coral sand has many pores, suspended fine particles or dissolved substances in the bath water are adsorbed thereon to keep the bath water clean.
In clinical trials hyperkalemia (serum potassium greater than 5.7 mEq/L) occurred in approximately 1.4% of hypertensive patients treated with lisinopril plus hydrochlorothiazide. In most cases these were isolated values which resolved despite continued therapy. Hyperkalemia was not a cause of discontinuation of therapy. Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes. Hyperkalemia can cause serious, sometimes fatal, arrhythmias. Lisinopril and hydrochlorothiazide should be used cautiously, if at all, with these agents and with frequent monitoring of serum potassium. (SeeDrug Interactions.)
Tropomyosin receptor kinases (Trks) are receptor tyrosine kinases activated by neurotrophic factors, called neurotrophins. Among them, TrkA interacts with the nerve growth factor (NGF), which leads to pain induction. mRNA-display screening was carried out to discover a hit compound 2, which inhibits protein-protein interactions between TrkA and NGF. Subsequent structure optimization improving phosphorylation inhibitory activity and serum stability was pursued using a unique process that took advantage of the peptide being synthesized by translation from mRNA. This gave peptide 19, which showed an analgesic effect in a rat incisional pain model. The peptides described here can serve as a new class of analgesics, and the structure optimization methods reported provide a strategy for discovering new peptide drugs.